CGEN Stock: Insider Activity, Filings & Research

Compugen Ltd. (CGEN) — Drillr’s hub for CGEN insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, CGEN insiders filed 0 open-market buys and 10 sales (SEC Form 4).

Sentiment

0/100

Buys (3m)

Sells (3m)

Net (3m)

-$113.6K

Insider trades by month Buys Sells

Mar

Apr

Context3-month price +2.3%Institutions mixed (13F)

Date	Insider	Type	Shares	Price
Apr 27, 2026	Levine Zuritofficer: SVP, Business Development	Option	2,000	$1.15
Apr 27, 2026	Levine Zuritofficer: SVP, Business Development	Sell	2,000	$3.20
Apr 27, 2026	Ophir Erandirector, officer: President and CEO	Option	5,000	$0.83
Apr 27, 2026	Ophir Erandirector, officer: President and CEO	Sell	5,000	$3.20
Apr 15, 2026	Levine Zuritofficer: SVP, Business Development	Sell	2,000	$2.80
Apr 15, 2026	Ophir Erandirector, officer: President and CEO	Option	5,000	$0.83
Apr 15, 2026	Ophir Erandirector, officer: President and CEO	Sell	5,000	$2.90
Apr 15, 2026	Levine Zuritofficer: SVP, Business Development	Option	2,000	$1.15
Apr 13, 2026	Levine Zuritofficer: SVP, Business Development	Sell	3,125	$2.56
Apr 13, 2026	Levine Zuritofficer: SVP, Business Development	Option	2,000	$1.15
Apr 13, 2026	Levine Zuritofficer: SVP, Business Development	Option	1,125	$0.83
Apr 9, 2026	Levine Zuritofficer: SVP, Business Development	Sell	5,375	$2.42
Apr 9, 2026	Levine Zuritofficer: SVP, Business Development	Option	2,500	$0.83
Apr 9, 2026	Levine Zuritofficer: SVP, Business Development	Sell	2,500	$2.30
Apr 9, 2026	Levine Zuritofficer: SVP, Business Development	Option	4,375	$0.83

Source: CGEN SEC Form 4 filings, latest Apr 27, 2026. For informational purposes only — not investment advice.

Overview

Compugen Ltd. (NASDAQ:CGEN) is an Israeli clinical-stage biotechnology company founded in 1993 and headquartered in Holon, Israel. The company went public in 2000 and has evolved from its origins in computational biology to become a focused immuno-oncology drug developer. Compugen utilizes its proprietary computational discovery platform to identify novel immune checkpoint targets and develops therapeutic antibodies to treat cancer patients. The company has established strategic partnerships with major pharmaceutical companies including AstraZeneca, Bayer, and Gilead Sciences to advance its pipeline of innovative cancer treatments.

Business

Compugen operates in the immuno-oncology sector of biotechnology, which focuses on harnessing the body's immune system to fight cancer. The company's core business involves discovering and developing therapeutic antibodies that target immune checkpoint proteins - molecular switches that regulate immune responses against tumors. The company's primary product candidates include: 1. COM701 - An anti-PVRIG antibody currently in Phase I clinical trials for solid tumors. PVRIG (Poliovirus Receptor-related Immunoglobulin domain-containing protein) is an immune checkpoint that suppresses T-cell activity. By blocking PVRIG, COM701 aims to enhance the immune system's ability to attack cancer cells, particularly in combination with other immunotherapies. 2. COM902 - A therapeutic antibody targeting TIGIT (T-cell Immunoreceptor with Ig and ITIM domains), another immune checkpoint protein. This antibody is designed to prevent immune suppression and boost anti-tumor immunity, currently being evaluated as monotherapy in Phase I studies. 3. Bapotulimab - An antibody targeting ILDR2 (Immunoglobulin Like Domain containing Receptor 2) in Phase I trials for solid tumors. 4. COM503 - A preclinical-stage antibody targeting IL-18 binding protein, which represents a novel approach to modulating the tumor microenvironment by enhancing inflammatory responses against cancer. The company also has partnership-derived assets, including AZD2936 (developed with AstraZeneca), a bi-specific antibody targeting both TIGIT and PD-1 pathways simultaneously. Compugen's computational discovery platform serves as the foundation for identifying these novel targets, using predictive algorithms and biological databases to uncover previously unknown immune regulatory mechanisms that can be therapeutically exploited.

Revenue model

Compugen generates revenue primarily through strategic partnerships and licensing agreements with pharmaceutical companies, rather than product sales, as its therapies are still in clinical development. The company's business model centers on three main revenue streams: 1. Upfront licensing payments and milestone fees - Compugen receives initial payments when partnering its drug candidates, followed by milestone payments as development progresses. For example, the company received a $30 million milestone from Gilead Sciences when COM503 received IND clearance, and has potential to earn up to $848 million total from this partnership. 2. Research collaboration fees - Partners pay for ongoing research and development activities. In 2024, Compugen reported $27.9 million in revenues, primarily from partnership agreements. 3. Future royalties - The company is entitled to royalty payments on net sales if partnered drugs reach commercialization, though none have reached this stage yet. The company's margins are significantly influenced by several factors. Positive margin drivers include the asset-light nature of computational drug discovery, which requires lower capital investment than traditional pharmaceutical R&D, and the ability to leverage partnerships to fund expensive clinical trials. The company's strong intellectual property portfolio, including favorable patent rulings, also supports pricing power. Margin pressures come from the inherently high-risk nature of drug development, where most candidates fail in clinical trials, leading to substantial R&D expenses without corresponding revenues. Competition in immuno-oncology is intense, with numerous companies developing checkpoint inhibitors, potentially limiting partnership terms. Additionally, the company faces regulatory risks, as clinical trial delays or failures can significantly impact milestone payments and partnership value. The current focus on challenging cancer indications like platinum-resistant ovarian cancer and microsatellite-stable colorectal cancer adds execution risk, as these represent areas where existing treatments have limited efficacy.

Risks & safety

Compugen presents a moderate margin of safety with strong liquidity but ongoing operational losses and execution risks typical of clinical-stage biotechnology companies. Liquidity and Solvency: • Cash position of $103.3 million as of December 2024 provides runway into 2027 • Strong current ratio of 5.26 indicates excellent short-term liquidity • Minimal debt with debt-to-equity ratio of only 0.053 • Positive free cash flow of $49.5 million in 2024, primarily from partnership payments • Low solvency risk given strong balance sheet and partnership funding Operational Metrics: • Net loss of $14.2 million in 2024, improved from $18.8 million in 2023 • Negative EBITDA of $14.4 million reflects ongoing R&D investment phase • Revenue of $27.9 million in 2024 demonstrates partnership traction • R&D expenses remain substantial but manageable within cash runway Valuation Considerations: • Trading at 2.49x book value, reasonable for biotech with strong balance sheet • Negative P/E ratio reflects development-stage nature • Enterprise value considerations complicated by negative EBITDA • Graham net-net ratio of 0.48 suggests potential asset value protection Other Risk Factors: • Clinical trial execution risk remains primary concern • Partnership dependency creates revenue concentration risk • Competitive pressures in immuno-oncology space • Regulatory approval uncertainty for novel checkpoint targets

Recent development

Over the past several years, Compugen has undergone a strategic transformation from a broad-based immuno-oncology company to a focused developer of combination therapies targeting specific cancer indications. The company concluded its collaboration with Bristol Myers Squibb and narrowed its clinical focus to two priority areas: platinum-resistant ovarian cancer and microsatellite-stable colorectal cancer, both representing significant unmet medical needs. The company's partnership strategy has intensified, with major deals reshaping its financial position and development priorities. The landmark agreement with Gilead Sciences for COM503, worth up to $848 million in total potential payments, represents a validation of Compugen's IL-18 binding protein approach. Similarly, AstraZeneca's advancement of rilvegostomig (derived from COM902) to Phase III trials in biliary tract cancer demonstrates the commercial potential of Compugen's TIGIT program. Clinical development has evolved toward combination approaches, with COM701 being studied in triple combination with COM902 and pembrolizumab, targeting the DNAM-1 axis pathway. This represents a shift from single-agent studies to more complex but potentially more effective combination strategies. The company has completed enrollment in its microsatellite-stable colorectal cancer study and is advancing platinum-resistant ovarian cancer trials. Platform expansion continues with COM503 advancing toward IND filing, representing Compugen's entry into IL-18 pathway modulation. The company has also strengthened its computational discovery capabilities and expanded its early-stage pipeline focused on myeloid targets, indicating continued innovation beyond its current clinical assets. The financial strategy has shifted toward non-dilutive funding, with management explicitly prioritizing partnerships over equity raises to preserve shareholder value while extending cash runway through 2027.

CGEN company profile · for informational purposes only — not investment advice.

Track CGEN with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free